sodium fusidate

DRUG3 trials

Sponsors

Arrevus Inc., Aceragen

Conditions

Acute Bacterial Skin and Skin Structure InfectionsCystic FibrosisCystic Fibrosis Pulmonary ExacerbationRefractory Bone or Joint Infections

Phase 2

Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections

CompletedNCT02569541

Arrevus Inc.Refractory Bone or Joint Infections

Start: 2015-12-31End: 2019-02-21Updated: 2020-01-30

Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations

WithdrawnNCT05641298

AceragenCystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation

Start: 2023-02-10End: 2023-09-30Updated: 2023-07-19

Phase 3

Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections

CompletedNCT02570490

Arrevus Inc.Acute Bacterial Skin and Skin Structure Infections

Start: 2015-11-30End: 2016-11-30Updated: 2019-04-19

Related Papers

A patient-centric paradigm and tool for clinical research: the DOOR is open.

UNC Libraries2026-01-16